---
schema_version: "secwatch.filing_event.v1"
accession: "0001232524-25-000061"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:28:44.819421+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Jazz Q2 GAAP net loss $718M; revenue $1.05B up 2%; updates FY25 guidance

## Summary
- Q2 total revenues $1.05B, up 2% YoY; GAAP net loss $718.5M vs $168.6M profit in Q2 2024.
- Non-GAAP adjusted net loss $504.8M vs $360.7M income; FY2025 revenue guidance revised to $4.15-$4.30B.
- Xywav revenue +13% to $415.3M; added ~625 net patients in Q2, active patients ~15,225.
- Renee Gala named President and CEO effective Aug 11; Bruce Cozadd becomes Chairman.
- FDA Priority Review for Zepzelca combo in 1L ES-SCLC (PDUFA Oct 7); dordaviprone PDUFA Aug 18.

## SEC filing metadata
- accession: 0001232524-25-000061
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000123252425000061/0001232524-25-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000123252425000061/jazz-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001232524-25-000061
- JSON: https://secwatch.observer/filing/0001232524-25-000061.json
- Plain text: https://secwatch.observer/filing/0001232524-25-000061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.